Please provide your email address to receive an email when new articles are posted on . The American College of Rheumatology and EULAR have officially released the first classification criteria for ...

CHICAGO — Classification criteria for IgG4-related disease, the first criteria drafted for the recently recognized condition, were presented during a press conference here at the American College of ...

Autoimmune diseases are a medical conundrum. In people with these conditions, the immune system of the body, the designated defense system, starts attacking the cells or organs of its own body, ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of patients ...

Adults with eosinophilic esophagitis (EoE) showed elevated levels of various food allergen–specific antibodies other than immunoglobulin G4 (IgG4), challenging the focus on IgG4 as a solitary marker ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune ...

Entering the fourth year of Covid-19, vaccination has become the frontline of protective measures to control the disease, as global nations have all but given up on mass mitigation strategies such as ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Antibodies to phosphorylcholine and carbohydrate determinants responsible for much of the cross-reactivity among nematodes are subclass restricted in humans and absent in the IgG4 subclass. Total IgG ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the ...

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...